Study Results from COTA, PreciseDx, and Baptist Health South Florida Confirm Novel AI Test, PreciseBreast is Equivalent to Oncotype DX at Predicting Breast Cancer Recurrence
Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ — COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence […]
